Elimusertib for Solid Cancers

Recruiting in Palo Alto (17 mi)

+28 other locations

Overseen byMichael V Ortiz

Age: < 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: National Cancer Institute (NCI)

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests elimusertib, a pill that blocks enzymes needed for cancer cell growth, in children and young adults with difficult-to-treat cancers. The drug aims to stop cancer cells from repairing and growing.

Research Team

Michael V Ortiz

Principal Investigator

Pediatric Early Phase Clinical Trial Network

Eligibility Criteria

This trial is for young patients (up to 30 years old) with solid tumors or lymphoma that have returned or are treatment-resistant. They must be able to swallow pills, not currently on other cancer treatments or strong CYP3A4 drugs, and can't have active brain metastases or uncontrolled infections.

Inclusion Criteria

I have a solid tumor or lymphoma diagnosis, not originating in the brain.

My cancer has come back or didn't respond to treatment, and was confirmed by a biopsy.

I can take care of myself but may not be able to do heavy physical work.

See 14 more

Exclusion Criteria

Patients currently receiving another investigational drug

Patients currently receiving other anti-cancer agents

Patients who may not be able to comply with the safety monitoring requirements of the study

See 7 more

Treatment Details

Interventions

Elimusertib (Protein Kinase Inhibitor)

Trial OverviewThe trial is testing Elimusertib's safety and optimal dosage in treating relapsed/refractory solid tumors. It aims to see if it can halt tumor growth by blocking enzymes needed for cell proliferation.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Treatment (elimusertib)Experimental Treatment1 Intervention

Patients receive elimusertib PO BID on days 1-3, 8-10, 15-17, and 22-24 of each cycle. Treatment repeats every 28 days for 26 cycles in the absence of disease progression or unacceptable toxicity.